Study confirms beneficial effect of Tri-Low full spectrum Amla extract upon dyslipidemia
March 22, 2019
Lipid balance was achieved with no concomitant reduction of plasma CoQ10 levels, a phenomenon typically associated with a number of lipid-lowering drugs. Other related parameters, such as fasting blood glucose, homocysteine levels, and apo-B/apo lipoprotein levels, also tended to lower. This potentially widens Tri-low’s scope for targeting diabetic dyslipidemia.
Are you a leader in research & development? Stay ahead of the curve with Prepared Foods, the premier source of information and insights for today's trend leaders and taste-makers in food and beverage manufacturing.
